| Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma T Yoshida, M Ri, S Kinoshita, T Narita, H Totani, R Ashour, A Ito, ... PLoS One 13 (5), e0196780, 2018 | 31 | 2018 |
| Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma R Ashour, M Ri, SS Aly, T Yoshida, T Tachita, T Kanamori, S Aoki, ... International Journal of Hematology 110, 69-76, 2019 | 13 | 2019 |
| Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits T Yoshida, M Ri, T Kanamori, S Aoki, R Ashour, S Kinoshita, T Narita, ... Oncotarget 9 (11), 9975, 2018 | 12 | 2018 |
| Identification of Circulating Serum microRNAs as Novel Biomarkers Predicting Disease Progression and Sensitivity to Bortezomib Treatment in Multiple Myeloma T Narita, M Ri, S Kinoshita, T Yoshida, H Totani, R Ashour, A Masaki, A Ito, ... Blood, The Journal of the American Society of Hematology 128 (22), 4408-4408, 2016 | 1 | 2016 |
| Anti-Myeloma Activity of a Syringolin Analog: A Dual 20S Proteasome Inhibitor of Beta 2 and 5 Subunits T Yoshida, M Ri, S Kinoshita, T Narita, H Totani, R Ashour, A Masaki, A Ito, ... Blood 128 (22), 4473, 2016 | | 2016 |
